GIST pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
26 of 32 arms with a reported figure. Choose arms to narrow the chart.
| Drug, trial | Population | Dose | Estimand | Comparator | ORR, % | mPFS, months | mOS, months | Hazard ratio | Other |
|---|---|---|---|---|---|---|---|---|---|
| Imatinib 400 mgImatinib Phase 3 dose trials (combined analysis on label) | unresectable or metastatic KIT (CD117) positive GIST | 400 mg | ITT | n/r | best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%) | median progression-free survival: 18.9 months, median follow up 37.5 months | median overall survival: 49 months, median follow up 37.5 months | n/r | n/r |
| Imatinib 800 mgImatinib Phase 3 dose trials (combined analysis on label) | unresectable or metastatic KIT (CD117) positive GIST | 800 mg | ITT | imatinib 400 mg | n/r | median progression-free survival: 23.2 months, median follow up 37.5 months | median overall survival: 48.7 months, median follow up 37.5 months | n/r | n/r |
| Imatinib 400 mgImatinib Phase 2 (400 vs 600 mg) | KIT (CD117) positive unresectable or metastatic GIST | 400 mg | ITT | imatinib 600 mg | objective response rate (SWOG): 68.5%, up to 36 months | n/r | n/r | n/r | n/r |
| Imatinib 600 mgImatinib Phase 2 (400 vs 600 mg) | KIT (CD117) positive unresectable or metastatic GIST | 600 mg | ITT | imatinib 400 mg | objective response rate (SWOG): 67.6%, up to 36 months | n/r | n/r | n/r | n/r |
| Imatinib 400 mgAdjuvant Study 1 (ACOSOG Z9001) | resected primary GIST 3 cm or more | 400 mg | ITT | placebo | n/r | n/r | n/r | recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 monthsrecurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months | n/r |
| Imatinib 400 mgAdjuvant Study 2 (SSG XVIII) | resected high-risk KIT positive GIST | 400 mg | ITT | imatinib for 12 months | n/r | n/r | n/r | recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 monthsoverall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months | n/r |
| Sunitinib 50 mgStudy 1 | GIST after imatinib progression or intolerance | 50 mg | ITT | placebo | objective response rate (partial responses): 6.8%, interim analysis | median time to tumor progression: 27.3 weeks, interim analysismedian progression-free survival: 24.1 weeks, interim analysis | n/r | n/r | n/r |
| Sunitinib placeboStudy 1 | GIST after imatinib progression or intolerance | placebo | ITT | This arm is placebo | n/r | median time to tumor progression: 6.4 weeks, interim analysismedian progression-free survival: 6 weeks, interim analysis | n/r | n/r | n/r |
| Regorafenib 160 mgGRID | GIST after imatinib and sunitinib | 160 mg | ITT | placebo | n/r | median progression-free survival: 4.8 months, primary analysis | median overall survival: 17.4 months, final OS analysis, 162 events | progression-free survival hazard ratio vs placebo: 0.27 HR, primary analysis | n/r |
| Regorafenib placeboGRID | GIST after imatinib and sunitinib | placebo | ITT | This arm is placebo | n/r | median progression-free survival: 0.9 months, primary analysis | median overall survival: 17.4 months, final OS analysis; 88% crossed over | n/r | n/r |
| Ripretinib 150 mgINVICTUS | GIST after imatinib, sunitinib and regorafenib | 150 mg | ITT | placebo | objective response rate (BICR): 9%, primary analysis | median progression-free survival (BICR): 6.3 months, primary analysis | median overall survival: 15.1 months, not tested for significance | progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis | n/r |
| Ripretinib placeboINVICTUS | GIST after imatinib, sunitinib and regorafenib | placebo | ITT | This arm is placebo | n/r | median progression-free survival (BICR): 1 months, primary analysis | median overall survival: 6.6 months, 66% switched to ripretinib | n/r | n/r |
| Ripretinib 150 mgINTRIGUE | GIST after imatinib (ITT n = 226) | 150 mg | ITT | sunitinib 50 mg 4/2 | objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03 | median progression-free survival (IRR), ITT: 8 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P | n/r | progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant | n/r |
| Ripretinib 50 mgINTRIGUE | GIST after imatinib (ITT n = 227) | 50 mg | ITT | n/r | objective response rate, KIT exon 11 ITT: 14.6%, primary analysis | median progression-free survival (IRR), ITT: 8.3 months, primary analysismedian progression-free survival, KIT exon 11 ITT: 7 months, primary analysismedian PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratorymedian PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory | n/r | n/r | n/r |
| Avapritinib 300 or 400 mgNAVIGATOR | unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43) | 300 or 400 mg | Single arm | n/r | overall response rate (independent review): 84%, median follow up 10.6 months | n/r | n/r | n/r | n/r |
| Avapritinib 300 or 400 mgNAVIGATOR | PDGFRA D842V (n = 38) | 300 or 400 mg | Single arm | n/r | overall response rate (independent review): 89%, median follow up 10.6 months | n/r | n/r | n/r | n/r |
| Avapritinib 300 or 400 mgNAVIGATOR | GIST, 267 patients in intracranial hemorrhage pooled count | 300 or 400 mg | Single arm | n/r | n/r | n/r | n/r | n/r | n/r |
| Avapritinib 300 mgVOYAGER | 3L or later GIST (n = 240) | 300 mg | ITT | regorafenib 160 mg | objective response rate: 17.1%, primary analysis | median progression-free survival: 4.2 months, primary analysis | n/r | progression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055 | n/r |
| Avapritinib 160 mgVOYAGER | 3L or later GIST (n = 236) | 160 mg | ITT | n/r | objective response rate: 7.2%, primary analysis | median progression-free survival: 5.6 months, primary analysis | n/r | n/r | n/r |
| Bezuclastinib + Sunitinib 600 mg + 37.5 mgPeak | GIST after imatinib (n = 204) | 600 mg + 37.5 mg | ITT | sunitinib 37.5 mg | objective response rate (BICR): 46%, data cutoff 09.30.2025 | median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025 | n/r | progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update | n/r |
| Bezuclastinib + Sunitinib 37.5 mgPeak | GIST after imatinib (n = 209) | 37.5 mg | ITT | n/r | objective response rate (BICR): 26%, data cutoff 09.30.2025 | median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025 | n/r | n/r | n/r |
| Velzatinib (IDRX-42, GSK6042981) 300 mgStrateGIST 1 | 2L advanced GIST (n = 46) | 300 mg | Single arm | n/r | objective response rate: 35%, cutoff 12.15.2025 | median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025 | n/r | n/r | n/r |
| Velzatinib (IDRX-42, GSK6042981) 300 mgStrateGIST 1 | 1L advanced GIST (n = 18) | 300 mg | Single arm | n/r | unconfirmed objective response rate: 61%, median follow up 6.4 months | n/r | n/r | n/r | n/r |
| Olverembatinib (HQP1351) 30 to 50 mgHQP1351SJ0003 | SDH-deficient GIST (n = 26) | 30 to 50 mg | Single arm | n/r | partial response as best response: 23.1%, cutoff 11.13.2025 | median progression-free survival: 25.7 months, cutoff 11.13.2025 | n/r | n/r | n/r |
| NB003 not stated in sourceNB003 Phase 1 | GIST 2L to 4L or later (n = 158) | not stated in source | Single arm | n/r | objective response rate: 28.5%, data as of March 2025 | median progression-free survival: 9.2 months, data as of March 2025 | n/r | n/r | n/r |
| NB003 not stated in sourceNB003 Phase 1 | GIST 3L (n not stated in source) | not stated in source | Single arm | n/r | objective response rate: 46.7%, data as of March 2025 | median progression-free survival: 13.7 months, data as of March 2025 | n/r | n/r | n/r |
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.